NCT03158922 (BARCODE1Pilot) is a clinical trial of Genetic SNP profiling in Prostate Cancer, sponsored by Institute of Cancer Research, United Kingdom.

Who is sponsoring NCT03158922?

NCT03158922 is sponsored by Institute of Cancer Research, United Kingdom.

What drugs are being tested in NCT03158922?

Interventions in NCT03158922: Genetic SNP profiling, Prostate cancer screening, Prostate biopsy.

What condition does NCT03158922 study?

NCT03158922 studies Prostate Cancer.

Is NCT03158922 still recruiting?

NCT03158922 is currently active, enrolled. Last updated 26 September 2025.

Last reviewed 2025-09-26 · How we verify

NCT03158922: BARCODE1Pilot

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The BARCODE 1 Pilot Study

Active, enrolled Last updated 26 September 2025

What this trial tests

trial testing Genetic SNP profiling in Prostate Cancer in 329 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

29 April 2016

Primary endpoint
14 April 2018

31 December 2028

Quick facts

Lead sponsor	Institute of Cancer Research, United Kingdom
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	329
Start date	29 April 2016
Primary completion	14 April 2018
Estimated completion	31 December 2028
Sites	1 location across United Kingdom

Drugs / interventions tested

Genetic SNP profiling
Prostate cancer screening
Prostate biopsy

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Institute of Cancer Research, United Kingdom

Who can join

Adults 55 to 69, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

BARCODE 1 is a screening study designed to investigate the role of genetic profiling for targeting population prostate cancer screening. This study forms a pilot of 300 men, with the view to continue to a future study of 5000 men.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

A Review of Prostate Cancer Genome-Wide Association Studies (GWAS).
Benafif S, Kote-Jarai Z, Eeles RA, PRACTICAL Consortium. · · 2018 · cited 120× · PMID 29348298 · DOI 10.1158/1055-9965.epi-16-1046
Complexities of Prostate Cancer.
Wasim S, Lee SY, Kim J. · · 2022 · cited 112× · PMID 36430730 · DOI 10.3390/ijms232214257

Verify or expand the search:

Other trials of Genetic SNP profiling

Trials testing the same drug.

NCT03857477 — The BARCODE 1 Study (Full Study): The Use of Genetic Profiling to Guide Prostate Cancer Targeted Screening. · active not recruiting

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Institute of Cancer Research, United Kingdom trials

Trials by the same sponsor.

NCT06396754 — Deployment and Clinical Evaluation of an AI-powered Digital Oncology Biomarker Tool to guidE Treatment in TNBC · not yet recruiting
NCT07391215 — 5G-PEARL: Paxalisib in Malignant Brain Tumours · Phase 1, PHASE2 · recruiting
NCT07098819 — The eValuation of Sources of vIBRAtioN for Vibrational Shear Wave elasTography · not yet recruiting
NCT06636526 — The i4i PRODICT® Study: Evaluation of the i4i PRODICT® Test in Different Ethnic Groups (The i4i PRODICT® Study). · recruiting
NCT06630260 — 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03158922 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Cancer Research, United Kingdom
Last refreshed: 26 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03158922.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing